{
  "url": "https://www.law.cornell.edu/regulations/new-york/8-NYCRR-63.6",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 8 ยง 63.6 - Registration and operation of New York establishments",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 8 ยง 63.6 - Registration and operation of New York establishments\n\nState Regulations\n(a) General provisions. (1)\n\nThe\nrequirements of this section shall apply to establishments located in New York\n\nState. Section\n63.8\nof this Part sets forth\nrequirements for the registration of nonresident establishments. (2)\nA certificate of registration issued for\nthe operation of a pharmacy, manufacturer, outsourcing facility or wholesaler\nshall be valid only for that address stated on the certificate. Endorsement of\nthe certificate to another address may be made by the State Board of Pharmacy\nupon application to the board, the payment of the fee set forth in Education\n\nLaw, section 6808, and a finding by the board that the new location meets the\nrequirements of the applicable subdivisions of this section. An application for\nendorsement to another address shall be made not less than 30 days prior to the\nexpected date of relocation. (3)\n\nIn\nthe case of a corporation, the State Board of Pharmacy shall be notified within\n30 days of any change in the officers of the corporation or in stockholders\nholding 10 percent or more of the stock in the corporation. (4)\n\nNo certificate of registration shall be\nissued or continued for the conduct of a pharmacy, manufacturer, outsourcing\nfacility or wholesaler unless the premises occupied by such registered\nestablishment shall be equipped with proper sanitary appliances and kept in a\nclean and orderly manner. (5)\n\nThe\n\nState Board of Pharmacy shall be notified within a period of 48 hours whenever\nany establishment registered by the board is damaged by fire, flood or other\ndisaster. (6)\n\nSigns on\nestablishments. Signs on establishments. Except as otherwise provided for pharmacies in general\nmerchandising establishments in paragraph (b)(5) of this section, a sign\nbearing the full name of the registrant shall be displayed prominently on the\nexterior of the premises in which a registered establishment is located, or in\nthe directory and on the immediate entrance to the registered establishment if\nit is located in a multi-tenanted structure. (7)\n\nElectronic prescriptions. (i) For the purposes of this section: (a) the term\nelectronic\nprescription\nmeans a prescription created, recorded or stored by\nelectronic means; issued and validated with an electronic signature; and\ntransmitted by electronic means; (b) the term\nelectronic\nmeans of or relating to technology having electrical, digital, magnetic, wireless, optical, electromagnetic, or similar capabilities; and\n(c) the term\nelectronic\nsignature\nmeans an electronic sound, symbol, or process, attached to\nor logically associated with an electronic prescription, executed or adopted by\na person with the intent to sign the prescription, and effectively secured from\nalteration by an unauthorized third party. (ii)\nA pharmacist may, based upon his or her\nprofessional judgment, accept an electronic prescription from a prescriber, to\nthe pharmacy of the patient's choice, subject to the following requirements: (a) the prescription shall contain the\nelectronic signature of the prescriber; (b) in the case of an electronic\nprescription, such prescription shall be electronically encrypted, meaning\nprotected to prevent access, alteration or use by any unauthorized\nperson; (c) an electronic\nprescription or a hard copy of an electronic prescription stored securely and\npermanently shall be maintained at the pharmacy for a period of five years from\nthe date of the most recent filling, provided that, if the prescription is\nmaintained electronically, it shall be made available to the department in hard\ncopy upon request; (d) except when\nthe prescriber inserts an electronic direction to dispense the drug as written, the prescriber's electronic signature shall designate approval of substitution\nby a pharmacist of a drug product pursuant to section\n206\n(1)(o)\nof the Public Health Law. Notwithstanding any other provision of this section or any other law to the\ncontrary, when a generic drug is not available and the brand name drug\noriginally prescribed is available and the pharmacist agrees to dispense the\nbrand name product for a price that will not exceed the price that would have\nbeen charged for the generic substitute had it been available, substitution of\na generic drug product will not be required. If the generic drug product is not\navailable and a medical emergency exists, which for purposes of this section\nshall be defined as a condition requiring the alleviation of severe pain or a\ncondition which threatens to cause disability or death if not promptly treated, the pharmacist may dispense the brand name product at the regular price. In\nsuch instances, the pharmacist shall record the date, hour and nature of the\nmedical emergency on the back of the prescription or within the electronic\nrecord of the prescription and shall keep a hard copy or electronic record of\nall such prescriptions; (e) except\nwhen the prescriber inserts an electronic direction to dispense the drug as\nwritten, the prescriber's electronic signature shall designate approval of an\ninterchangeable biological product by a pharmacist. Notwithstanding any other\nprovision of this section or any other law to the contrary, when an\ninterchangeable biological product is not available and the biological product\noriginally prescribed is available and the pharmacist agrees to dispense the\nprescribed biological product for a price that will not exceed the price that\nwould have been charged for the interchangeable biological substitute had it\nbeen available, substitution of an interchangeable biological product will not\nbe required. If the interchangeable biological product is not available and a\nmedical emergency situation, which for purposes of this section is defined as\nany condition requiring alleviation of severe pain or which threatens to cause\ndisability or take life if not promptly treated, exists, then the pharmacist\nmay dispense the prescribed biological product at his or her regular price. In\nsuch instances, the pharmacist must record the date, hour and nature of the\nmedical emergency on the back of the prescription and keep a copy of all such\nprescriptions; (f) such\nprescriptions shall be processed in accordance with the requirements of section\n29.7\nof this Title, provided, however, that prescriptions for controlled substances shall be filled in\naccordance with the requirements of article 33 of the Public Health Law; and\n(g) in accepting an electronic\nprescription, the pharmacist shall be subject to the applicable requirements of\n\nPart 29 of this Title relating to unprofessional conduct, including but not\nlimited to section\n29.1\n(b)(2) and (3)\nof this Title. (iii)\n\nAn\noriginal hard copy prescription that is created electronically or otherwise may\nbe transmitted from the prescriber to the pharmacist by facsimile and must be\nmanually signed, provided, however, that prescriptions for controlled\nsubstances shall be filled in accordance with the requirements of article 33 of\nthe Public Health Law. A permanent hard copy of a prescription transmitted by\nfacsimile shall be stored securely and permanently in hard copy or by\nelectronic means and shall be maintained at the pharmacy for a period of five\nyears from the date of the most recent filling, provided that if the\nprescription is maintained electronically, it shall be made available to the\ndepartment in hard copy upon request. (8)\n\nRefill transfers. Except for a\nprescription for a controlled substance under article 33 of the Public Health\n\nLaw, pharmacists at registered pharmacies may, at the express request and\napproval of a patient or a person authorized to act on behalf of the patient, transfer prescription information to, or accept a transfer from, another\nregistered pharmacy or a pharmacy authorized to do business in another\njurisdiction for the exclusive purpose of providing one authorized refill per\ntransfer, subject to requirements of this paragraph. (i) A pharmacist at a registered pharmacy may\ntransfer original prescription information required by section\n29.7\n(a)(1)\nof this\n\nTitle, to another pharmacy for the purpose of providing one authorized refill\nper transfer, provided that the original prescription information is\ntransferred directly from one pharmacist to another pharmacist. Such transfer\nof prescription information may be accomplished by oral or written\ncommunication or by electronic transmission. The pharmacist at a registered\npharmacy who transfers original prescription information shall record the\nfollowing information: (a) the fact that an\nauthorized refill of the prescription has been transferred; (b) the name, address and telephone number of\nthe pharmacy to which it was transferred; (c) the name of the pharmacist receiving the\nprescription information; (d) the\nname of the pharmacist transferring the information; and\n(e) the date of the transfer. (ii)\nA pharmacist at a registered\npharmacy may accept the original prescription for the purpose of providing one\nauthorized refill per transfer, provided that the original prescription\ninformation is transferred from one pharmacist to another pharmacist. The\npharmacist at a registered pharmacy who accepts the original prescription\ninformation shall: (a) obtain all information\nrequired by section\n29.7\n(a)(1)\nof this\n\nTitle; (b) produce a hard copy of\nsuch information and ensure that the term \"refill transfer\" appears on the face\nof the hard copy; and\n(c) record\nthe dates of original and most recent filling or transfer of the original\nprescription, the transferring pharmacy's name and address, the original\nprescription number from which the prescription was transferred, the name of\nthe pharmacist transferring the prescription, and the name of the pharmacist\nreceiving the transfer. (iii)\n\nSystems providing for the electronic\ntransfer of prescriptions shall not infringe on a patient's freedom of choice\nas to the provider of pharmaceutical care. (iv)\n\nThe hard copy of the transferred\nprescription shall be maintained for a period of five years from the date of\nfilling. (iv)\nA pharmacy utilizing\nautomated data processing systems to transfer a prescription refill or to\naccept a prescription refill shall satisfy the requirements of this subdivision\nand shall also meet the requirements of paragraph (9) of this subdivision if\nthe pharmacy accesses a common electronic file or database used to maintain\nrequired personally identifiable dispensing information. (9)\nA pharmacy that accesses a common\nelectronic file or database used to maintain required personally identifiable\ndispensing information shall only access such information upon the express\nrequest of the patient or a person authorized to act on behalf of the patient. Such common file shall contain complete records of each prescription and refill\ndispensed. (b) Pharmacies. (1)\n\nTo secure and\nretain registration, a pharmacy shall be equipped with at least the following\nutensils: (i) weighing device sensitive to 6\nmg; (ii)\nmetric weights, if needed\nfor the operation of the device in subparagraph (i) of this\nparagraph; (iii)\ndevices capable of\nmeasuring volumes from 0.1 ml to 500 ml; and\n(iv)\na mortar and pestle. (2)\n\nThe registered area shall\nmeasure not less than 300 square feet and shall include a manufacturing, compounding and dispensing area of not less than 100 square feet. The pharmacy\nshall be equipped with storage facilities providing for the safe storage of\ndrugs; with heating and ventilation adequate to safeguard the purity and\npotency of drugs; with adequate lighting; and with hot and cold running water\nin the compounding and dispensing area; provided, however, that a pharmacy\nwhich was registered initially prior to the effective date of this paragraph on\nthe basis of meeting requirements less than those specified in this paragraph\nshall not be required to meet the requirements of this paragraph for the\ncontinuance of registration to the same registrant. (3)\n\nThe registered area shall include a\nrefrigerator, sufficient in capacity to serve the needs of the pharmacy, that\nis equipped with a thermometer and providing at all times a storage temperature\nof 2 degrees to 8 degrees Centigrade (36 degrees to 46 degrees Fahrenheit). The\nuse of such refrigerator shall be limited to the storage of drugs. (4)\n\nThe pharmacy shall possess copies of\nlaws, rules and regulations governing the practice of pharmacy in New York, and\nother reference resources as may be necessary to carry on the practice of\npharmacy. (5)\nA pharmacy operated\nas a department of a general merchandising establishment shall be enclosed\npermanently by a partition at least nine feet six inches in height, except\nwhere the ceiling is less than nine feet six inches in height in which case the\npartition shall be from floor to ceiling. Identification of such department by\nuse of words \"drugs,\" \"medicines,\" \"drug store\" or \"pharmacy\"; or similar terms\nshall be restricted to the area registered by the department, except that\nnothing in this restriction shall prevent the placement on the exterior of such\nestablishment of signs indicating the existence of a pharmacy therein. Such\nexterior signs may consist of the name of the registrant and/or the word\npharmacy; provided, however, that when the word\npharmacy\nis used, it may not be used in juxtaposition to a\nnonregistered name. When the pharmacy is not open during all the hours\nmaintained by the general merchandising establishment, an exterior sign shall\nindicate clearly when the pharmacy is open and when it is closed. (6)\nA pharmacy in which radioactive drugs are\ndispensed shall meet all requirements established by 10 NYCRR Part\n16\nfor\nmedical and academic facilities or by 12 NYCRR Part\n38\nfor commercial\nfacilities as evidenced by receipt by the pharmacy of an appropriate license\nissued by the New York State Department of Health or the New York State\n\nDepartment of Labor, and the additional requirements which follow. (i) There shall be present at all hours when\nthe pharmacy is open at least one pharmacist who: (a) meets the minimal standards of training\nand experience required by 10 NYCRR Part\n16\nor by 12 NYCRR Part\n38\nfor the use\nof radioactive materials; and\n(b) has submitted to the State Board of Pharmacy evidence of either of the\nfollowing: (1)\ncertification as a Nuclear\n\nPharmacist by the Board of Pharmaceutical Specialties of the American\n\nPharmaceutical Association; or\n(2)\ncompletion of a minimum of 200 contact hours of didactic instruction in nuclear\npharmacy in an accredited school or college of pharmacy, and a minimum of 500\nhours of clinical nuclear pharmacy training under the supervision of a Board of\n\nPharmaceutical Specialties certified nuclear pharmacist in a pharmacy providing\nnuclear pharmacy services, in a certified nuclear pharmacy residency program or\nin a nuclear pharmacy training program in an accredited school or college of\npharmacy or the equivalent thereof as determined by the department. (ii)\n\nIn addition to the\nitems and articles of equipment required by this subdivision, the pharmacy\nshall be equipped with at least the following: (a) laminar flow hood; (b) dose calibrator; (c) exhaust hood and filter system; (d) chromatography apparatus; (e) apparatus or materials for the\ndetermination of pH; (f) single-channel and/or multichannel scintillation detection system; and\n(g) microscope. (iii)\nA pharmacy which dispenses\nboth radioactive drugs and nonradioactive drugs shall maintain a separate area\nfor the storage and dispensing of radioactive drugs, which area shall be\nsecured from unauthorized personnel. (7)\n\nPatient medication profile. Each\npharmacist shall maintain a patient medication profile. Such medication profile\nshall include, but not be limited to, the patient's name, address, telephone\nnumber, gender, date of birth or age, known allergies and drug reactions, chronic diseases, a comprehensive list of medications and relevant devices and\nother information reported to the pharmacist appropriate for counseling an\nindividual regarding use of prescription and over-the-counter drugs. Pharmacists or pharmacy interns shall conduct a prospective drug review before\neach prescription is dispensed or delivered to a patient or person authorized\nto act on behalf of the patient. Such review shall include screening for\npotential drug therapy problems due to therapeutic duplication, drug-drug\ninteractions, including serious interactions with over-the-counter drugs, incorrect drug dosage or duration of drug treatment, drug-allergy interactions, and clinical abuse or misuse. Patient medication profiles shall be maintained\nin a retrievable form for five years following the date of the most recent\nentry. (8)\n\nCounseling. (i) On-premises delivery. For a prescription\nthat is delivered to a patient or a person authorized to act on behalf of the\npatient on the premises of the pharmacy, the pharmacist or pharmacy intern\nshall meet the requirements of this subparagraph. For a prescription that is\ndelivered to a patient or a person authorized to act on behalf of the patient\noff the premises of a pharmacy through mail delivery, a delivery service or\notherwise, the pharmacist or pharmacy intern shall meet the requirements of\nsubparagraph (ii) of this paragraph. (a) Prior to dispensing a prescription for the first time for a new patient of the\npharmacy or a prescription for a new medication for an existing patient of the\npharmacy and/or a change in the dose, strength, route of administration or\ndirections for use of an existing prescription previously dispensed for an\nexisting patient of the pharmacy, a pharmacist or pharmacy intern providing\nprescription services shall be required to personally counsel each patient or\nperson authorized to act on behalf of a patient who presents a prescription, consistent with the provisions of section\n29.1\n(b)(8)\nof this\n\nTitle, in person in a face-to-face meeting whenever practicable, or by\ntelephone, matters which in the exercise of the pharmacist's or pharmacy\nintern's professional judgment, the pharmacist or pharmacy intern deems\nappropriate, which may include: (1)\nthe name\nand description of the medication and known indications; (2)\ndosage form, dosage, route of\nadministration and duration of drug therapy; (3)\nspecial directions and precautions for\npreparation, administration and use by the patient; (4)\ncommon severe side or adverse effects or\ninteractions and therapeutic contraindications that may be encountered, including their avoidance, and the action required if they occur; (5)\ntechniques for self-monitoring drug\ntherapy; (6)\nproper\nstorage; (7)\nprescription refill\ninformation; and\n(8)\naction to be\ntaken in the event of a missed dose. (b) The counseling of a patient or person\nauthorized to act on behalf of a patient pursuant to clause\n(\na\n) of this subparagraph shall be provided personally by the\npharmacist or the pharmacy intern and shall not be delegated to an individual\nnot authorized to practice pharmacy under a license or limited\npermit. (c) In the event a patient\nrefuses to supply information necessary for maintenance of a medication\nprofile, or to accept counseling, as prescribed in clause (\na\n)\nof this subparagraph, a pharmacist or pharmacy intern may fill a prescription\nas presented, without having violated the requirements of this subparagraph, provided that the refusal to provide such information or accept counseling is\ndocumented in the records of the pharmacy. (d) In the event a patient or a person\nauthorized to act on behalf of a patient seeks to obtain a refill of an\nexisting prescription previously filled by the pharmacy or an authorization for\ncontinuation of an existing therapy, a pharmacist or pharmacy intern shall be\navailable to provide counseling to the patient or person authorized to act on\nbehalf of a patient, upon such person's request. In such circumstances and\nconsistent with the requirements of section\n29.7\n(a)(21)\nof\nthis Title, an offer to counsel the patient or a person authorized to act on\nbehalf of a patient may be conveyed on behalf of the pharmacist or pharmacy\nintern by an unlicensed assistant. Such counseling shall be conducted only by a\npharmacist or pharmacy intern. (e) Nothing in this subparagraph shall prevent a pharmacist or pharmacy intern from\nrefusing to dispense a prescription if, in his or her professional judgment, potential adverse effects, interactions or other therapeutic complications\ncould endanger the health of the patient. (ii)\n\nOff-premises delivery. For a\nprescription that is delivered to the patient or the person authorized to act\non behalf of the patient off the premises of the pharmacy through mail\ndelivery, a delivery service or otherwise, the pharmacist or pharmacy intern\nshall meet the requirements of this subparagraph. (a) Upon dispensing a prescription, a\npharmacist or pharmacy intern shall include with each prescription a written\noffer to counsel the patient or person authorized to act on behalf of the\npatient who presents the prescription. The written offer of counseling shall\nadvise the patient or the person authorized to act on behalf of the patient of\nthe availability of counseling on topics, which shall include but not be\nlimited to, the topics listed in subclauses\n(i)(\na\n)(\n1\n) through (\n8\n) of\nthis paragraph and that a licensed pharmacist or pharmacy intern authorized to\npractice pharmacy is available to provide the counseling. The written offer to\ncounsel shall provide a telephone number at which a licensed pharmacist or\npharmacy intern may be readily reached. For pharmacies engaged primarily in the\nmail order delivery of prescriptions, that telephone number shall be toll-free\nfor long distance calls. (b) When a\npatient or person authorized to act on behalf of the patient requests\ncounseling pursuant to the written offer of counseling, the pharmacist or\npharmacy intern shall personally counsel that person, consistent with the\nprovisions of section 29.l(b)(8) of this Title, to the extent the pharmacist or\npharmacy intern deems appropriate in his or her professional judgment. Such\ncounseling may include the topics listed in subclauses\n(i)(\na\n)(\n1\n) through (\n8\n) of\nthis paragraph. Such counseling shall be conducted via telephone or in an\nin-person face-to-face meeting. (c) Except for instances covered by clause (d) of this subparagraph, which applies\nin those cases, if upon presentation of the prescription, the pharmacist or\npharmacy intern determines that the prescription is a prescriber approved\nalternative drug, meaning a change in the drug originally prescribed exclusive\nof generic substitutions or interchangeable biological product substitutions, the pharmacist or pharmacy intern shall meet the following requirements in\naddition to the requirements of clauses (a) and (b) of this subparagraph: (1)\n\nUpon dispensing the prescription, the\npharmacist or pharmacy intern shall include with each prescription a special\nwritten notification that clearly advises the patient or the person authorized\nto act on behalf of the patient that a prescriber approved alternative drug has\nbeen dispensed, the directions for the use of such drug and the availability of\ncounseling on the drug. (2)\n\nExcept\nfor the cases set forth in subclause (\n3\n) of this clause, the\npharmacist or pharmacy intern shall make a reasonable effort to contact the\npatient or person authorized to act on behalf of the patient by telephone in\norder to personally offer counseling to that person about the prescriber\napproved alternative drug and other matters which in the exercise of the\npharmacist's or pharmacy intern's judgment, he or she deems appropriate, consistent with the provisions of section\n29.1\n(b)(8)\nof this\n\nTitle, including topics prescribed in subclauses\n(i)(\na\n)(\n1\n) through (\n8\n) of\nthis paragraph. The effort to contact the patient or person authorized to act\non behalf of the patient by telephone may commence after the drug is mailed or\ndelivered to that person. A reasonable effort to contact the patient or the\nperson authorized to act on behalf of the patient by telephone shall mean at\nleast two attempts to reach the patient or person authorized to act on behalf\nof the patient through telephone calls placed to such person by 48 hours after\nmailing or delivering the prescription. (3)\n\nThe pharmacist or pharmacy intern shall\nnot be required to make an effort to contact the patient or the person\nauthorized to act on behalf of the patient by telephone, as prescribed in\nsubclause (\n2\n) of this clause, if the patient or the person\nauthorized to act on behalf of the patient does not have a telephone at which\nhe or she may be reached, or if such person refuses to provide a telephone\nnumber at which he or she may be reached, or if such person has indicated to\nthe pharmacy that he or she does not wish to be contacted by telephone for\ncounseling. (4)\n\nThe pharmacy shall\ndocument the efforts made to contact the patient or the person authorized to\nact on behalf of the patient by telephone, or alternatively, the fact that the\npatient or person authorized to act on behalf of the patient either does not\nhave a telephone at which he or she may be reached or refuses to provide a\ntelephone number at which he or she may be reached or has indicated to the\npharmacy that he or she does not wish to be contacted by telephone for\ncounseling. (5)\n\nThe offer to\ncounsel the patient or the person authorized to act on behalf of the patient\nshall be provided personally by the pharmacist or the pharmacy intern and shall\nnot be delegated to an individual not authorized to practice pharmacy under a\nlicense or limited permit. (6)\n\nIf\nthe offer of counseling is accepted, the pharmacist or pharmacy intern shall\ncounsel the patient or the person authorized to act on behalf of the patient to\nthe extent that the pharmacist or pharmacy intern deems appropriate in his or\nher professional judgment, as prescribed in subclause (\n2\n) of\nthis clause. (7)\n\nIf the offer of\ncounseling is not accepted, the refusal to accept counseling shall be\ndocumented in the records of the pharmacy. (d) If upon presentation of the prescription, the pharmacist or pharmacy intern determines that there are potential drug\ntherapy problems which could endanger the health of the patient, including but\nnot limited to: therapeutic duplication, drug-drug interactions and\ndrug-allergy interactions, the pharmacist or pharmacy intern shall be subject\nto the following requirements in addition to the requirements of clauses\n(\na\n) and (\nb\n) of this subparagraph: (1)\n\nPrior to dispensing the prescription, the\npharmacist or pharmacy intern shall personally contact the patient or person\nauthorized to act on behalf of the patient via telephone or through an\nin-person face-to-face meeting to offer counseling on the identified potential\ndrug therapy problems and other matters which in the exercise of the\npharmacist's or pharmacy intern's judgment, he or she deems appropriate, consistent with the provisions of section\n29.1\n(b)(8)\nof this\n\nTitle, including topics prescribed in subclauses\n(i)(\na\n)(\n1\n) through (\n8\n) of\nthis paragraph. (2)\n\nThe offer to\ncounsel the patient or the person authorized to act on behalf of the patient\nshall be provided personally by the pharmacist or the pharmacy intern and shall\nnot be delegated to an individual not authorized to practice pharmacy under a\nlicense or limited permit. (3)\n\nIf\nthe offer of counseling is accepted, the pharmacist or pharmacy intern shall\ncounsel the patient or the person authorized to act on behalf of the patient to\nthe extent that the pharmacist or pharmacy intern deems appropriate in his or\nher professional judgment, as prescribed in subclause (\n1\n) of\nthis clause. (4)\n\nIf the offer of\ncounseling is not accepted, the refusal to accept counseling shall be\ndocumented in the records of the pharmacy. (5)\n\nNothing in this subparagraph shall\nprevent a pharmacist or pharmacy intern from refusing to dispense a\nprescription if, in his or her professional judgment, potential adverse\neffects, interactions or other therapeutic complications could endanger the\nhealth of the patient. (9)\n\nDrug retail price lists. Every registered\npharmacy that sells prescription medications at retail shall meet the\nrequirements of section\n6826\nof the\n\nEducation Law. In accordance with subdivision (4) of section\n6826\nof the\n\nEducation Law, such registered pharmacies shall have a sign notifying people of\nthe availability of the drug retail price list, conspicuously posted at or\nadjacent to the place in the pharmacy where prescriptions are presented for\ncompounding and dispensing, in the waiting area for customers, or in the area\nwhere prescribed drugs are delivered. The sign shall state in bold, block\nletters of at least one inch in height: \"Drug Retail Price List Available Upon\n\nRequest.\" Such registered pharmacies that offer to dispense prescription drugs\nto consumers through a website on the Internet shall post on such website a\nnotice of the availability of the drug retail price list and a toll-free\ntelephone number to obtain the list. Such registered pharmacies that offer to\ndispense prescription drugs to consumers through mail order shall include a\nprinted notice with each delivery of a prescription drug informing the consumer\nof the availability of the drug retail price list and a toll-free telephone\nnumber to obtain the list. (c) Manufacturers, outsourcing\nfacilities and wholesalers. (1)\n\nExcept\nas provided in paragraph (2) of this subdivision, no manufacturer or wholesaler\nshall be registered pursuant to the provisions of subdivision 4 of section\n6808\nof the\n\nEducation Law and no outstanding facility shall be registered pursuant to the\nprovisions of subdivision 5 of section\n6808\nof the\n\nEducation Law unless a registered pharmacist is present at all times when the\nestablishment is open for business; provided, however, that establishments\nregistered as a manufacturer or wholesaler under this section may be under the\nsupervision of an individual who has at least two years of experience in the\nmanufacturing, repacking and/or wholesaling of drugs satisfactory to the\ndepartment and is either: (i) a chemist who\nholds a bachelor's degree in chemistry; or\n(ii)\nan individual who holds a bachelor's\ndegree in pharmaceutical manufacturing, biochemistry, microbiology or other\nbachelor's degree deemed satisfactory to the department. (2)\n\nWholesalers who do not repack may\ndesignate as the supervisor a person who presents evidence of the completion of\na minimum of two years of education beyond high school and who has at least two\nyears of experience in the manufacturing, repacking and/or wholesaling of drugs\nsatisfactory to the State Board of Pharmacy. Establishments which limit their\noperation to manufacturing and repacking of compressed medical gases and/or\nwholesaling of related respiratory therapy agents may be under the supervision\nof: (i) a respiratory therapist certified by\na national accrediting body; (ii)\na\nperson holding a bachelor's degree in chemistry, microbiology, chemical\nengineering or a related field; or\n(iii)\na person having two years of education\nbeyond high school and two years experience in the handling of compressed\nmedical gases satisfactory to the State Board of Pharmacy. (3)\n\nSupervisor requirements for wholesalers\ntransfilling medical oxygen. Wholesalers that transfill medical oxygen shall\nensure any person responsible for supervising the transfilling of medical\noxygen is either: (i) a respiratory therapist\ncertified by a national accrediting body; (ii)\na person holding a bachelor's degree in\nchemistry, microbiology, chemical engineering or a related field; (iii)\na person having two years of education\nbeyond high school and two years of experience in the handling of compressed\nmedical gases satisfactory to the state board of pharmacy; or\n(iv)\na person having training in accordance\nwith the requirements established in\nsection\n211.25\nof title 21 of the code of federal\nregulations. (4)\n\nThe supervisor of an establishment\ndesignated pursuant to paragraphs (1), (2), and (3) of this subdivision shall\nnot be at the same time the supervisor of any other establishment registered by\nthe board. (5)\n\nThe size and\nfacilities of a registered establishment shall be appropriate for the\nactivities to be conducted therein. The area to be registered shall measure no\nless than 300 square feet. The registered area shall not be shared with or be\ndevoted in part to any other business. The registered establishment shall be in\ncompliance with at least the minimum requirements as provided in\nsection\n205.50\nof title 21 of the Code of Federal\n\nRegulations (Code of Federal Regulations, 1991 edition, Superintendent of Documents, U.S. Government Printing Office, Washington, DC\n20402: 1991--available at New York State Board of Pharmacy, Office of the\n\nProfessions, 89 Washington Ave., 2nd Floor, Albany, NY 12234). (6)\n\nManufacturers, outsourcing facilities or\nwholesalers shall sell drugs and/or devices only to those purchasers authorized\nby law. Records of the receipt and disposition of all drugs and/or devices\nshall be maintained for a period of five years and shall be available to the\ndepartment for review and copying upon request. (7)\n\nCertification of manufacturers and\nwholesalers for export purposes. Any registered manufacturer or wholesaler may\nbe issued a certificate by the executive secretary of the State Board of\n\nPharmacy or a designee of the Commissioner of Education, authenticating said\nregistration and identifying the specified drugs and/or devices as articles\nregularly offered for sale in New York. The fee for each certificate shall be\n$5. (8)\n\nAdditional requirements for\noutsourcing facilities. (i) Upon initially\nregistering as an outsourcing facility and every six months thereafter, each\noutsourcing facility shall submit to the executive secretary of the State Board\nof Pharmacy a report, on a form prescribed by the commissioner, which shall\ninclude, but not be limited to: (a) identification of the drugs compounded by such outsourcing facility during the\nprevious six-month period; and\n(b) with respect to each such identified drug, provide the active ingredient; the\nsource of such active ingredient; the national drug code number of the source\ndrug or bulk active ingredient, if available; the strength of the active\ningredient per unit; the dosage form and route of administration; the package\ndescription; the number of individuals units produced; and the national drug\ncode number of the final product, if assigned. (ii)\n\nOutsourcing facilities shall maintain\nquality control records for determining beyond use dating and stability for\nfive years and shall make such records available to the department for review\nand copying upon request. (iii)\n\nOutsourcing facilities shall comply with the special provisions relating to\noutsourcing facilities set forth in Education Law section 6831. (iv)\n\nOutsourcing facilities shall comply with\ncurrent good manufacturing practices as specified in parts 210 and 211 of title\n21, Code of Federal Regulations\n(2013 edition, Superintendent\nof Documents, U.S. Government Printing Office, Washington DC 20402; 2013, available at New York State Board of Pharmacy, 2nd Floor, Education Building, 89 Washington Avenue, Albany, NY 12234). (v) At all times such facilities shall be\nunder the supervision of a pharmacist licensed and registered to practice\npharmacy in New York State. (vi)\n\nUpon initial registration and at each renewal, such facilities shall submit to\nthe department documentation that the facility is registered as an outsourcing\nfacility under the Federal Food, Drug and Cosmetic Act. (vii)\n\nUpon initial registration and at least\nannually thereafter, such facilities shall submit to the department the results\nof an inspection by either: representatives of the Federal Food and Drug\n\nAdministration, this department or a third party acceptable to the\ndepartment. (viii)\n\nNo outsourcing\nfacility may distribute or dispense any drug to any person pursuant to a\nprescription unless it is also a New York State registered pharmacy and meets\nall other applicable requirements of Federal and State law. (ix)\n\nOutsourcing facilities that fail to\ndemonstrate that the facility is registered as an outsourcing facility under\nthe Federal Food, Drug and Cosmetic Act shall not meet the requirements for\nrenewal of registration. (d) The commissioner, upon recommendation of\nthe Board of Pharmacy, may in his or her discretion waive regulations in this\n\nPart in order to allow the initiation and evaluation of demonstration projects\nusing emerging technologies and practices in the profession of pharmacy, if the\ncommissioner determines that such waiver does not violate a statutory\nrequirement or a rule of the Board of Regents, is consistent with existing\nstatutory and regulatory intent, and that such waiver will not diminish patient\nsafety or consumer protections. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 8\nยง\n63.6\n\nAmended, New\n\nYork State Register October 1, 2014/Volume XXXVI, Issue 39, eff. 10/1/2014\n\nAmended\n\nNew\n\nYork State Register April 25, 2018/Volume XL, Issue 17, eff. 4/25/2018\n\nAmended\n\nNew\n\nYork State Register September 25, 2019/Volume XL, Issue 39, eff. 9/25/2019\n\nAmended\n\nNew\n\nYork State Register July 31, 2024/Volume XLVI, Issue 31, eff. 7/15/2024, exp. 9/12/2024\n(Emergency)\n\nAmended\n\nNew\n\nYork State Register September 25, 2024/Volume XLVI, Issue 39, eff. 9/25/2024\n\nAmended\n\nNew\n\nYork State Register October 2, 2024/Volume XLVI, Issue 40, eff. 9/13/2024, exp. 11/11/2024\n(Emergency)\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 39244
}